One-Hour Briefing
Life-sciences companies frequently must determine what (if anything) to disclose about key developments in clinical trials or the Food and Drug Administration’s (“FDA”) review process. Determining what to disclose requires great nuance, especially because disclosure may be required even when a company has only incomplete information. This Briefing will provide best practices for life-sciences companies to reduce litigation risk -- ...